|Abacavir||Nucleotide analogue reverse transcriptase inhibitor|
|Lamivudine||Nucleotide analogue reverse transcriptase inhibitor|
|Pregnancy cat.||C (US)|
|Legal status||POM (UK) ℞-only (US)|
|(what is this?)|
Abacavir/lamivudine (INNs) is a combination drug for the treatment of HIV infection. It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom. It is a fixed dose combination of lamivudine (3TC, Epivir) and abacavir (ABC, Ziagen).
Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).
It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|